Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

5.725 -0.125 (-2.14%)
Streaming Delayed Price Updated: 9:30 AM EDT, May 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On?
Altimmune stock rose on Tuesday without news, possibly due to high short interest. Its new trial for Alcohol Use Disorder and upcoming MASH results may be fueling excitement. 
Via Benzinga
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased
In the second quarter, the firm expects to announce data from a phase 2 trial of its investigational therapy, Pemvidutide, in treating metabolic dysfunction-associated steatohepatitis (MASH). 
Via Stocktwits
What to Expect from Altimmune's Earnings
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
What's Going On With Altimmune (ALT) Stock Today?
Altimmune shares jumped 8.5% on Friday. The stock is higher ahead of next week's presentation at the European Association for the Study of the Liver International Liver Congress. 
Via Benzinga
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Earnings Scheduled For February 27, 2025
Via Benzinga
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Scheduled For May 13, 2025
Via Benzinga
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Via The Motley Fool
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition. 
Via Benzinga
8 Analysts Assess Altimmune: What You Need To Know
Via Benzinga
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Via The Motley Fool
Altimmune Shares Sink This Year, But Retail Traders See A Buyout On The Horizon
A Betaville report suggested Altimmune has begun a strategic review with an adviser, with speculation that three major pharmaceutical firms may be involved. 
Via Stocktwits
Decoding 4 Analyst Evaluations For Altimmune
Via Benzinga
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders
Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits. 
Via Benzinga
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print
The company plans to unveil details at its virtual R&D Day on March 13. 
Via Stocktwits
Exposures Product Safety
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Mastering Market Chaos: StoryTrading’s Top 5 Stocks You Can’t Ignore
The trading landscape is alive with opportunity, shaped by a mix of macroeconomic events and sector-specific moves. 
Via Talk Markets
Topics Stocks / Equities
Pure Storage Posts Upbeat Results, Joins Cross Country Healthcare, Marvell Technology, Stoke Therapeutics And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Via Benzinga
MarketBeat Week in Review – 11/4 - 11/8
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts 
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political
How Altimmune Could Grab a Big Chunk of the GLP-1 Market
Altimmune is working on a developmental weight loss drug that could have strong benefits for an important segment of GLP-1 users. 
Via MarketBeat
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns. 
Via Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Telemedicine once seemed like it was going to revolutionize healthcare. 
Via The Motley Fool
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.